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Abstract
Copy number variations (CNVs) are gains and losses of DNA segments in 
the human genome, and form genetic variations. Recent studies have 
shown that CNVs contribute to the phenotypic variation in humans and 
are associated with complex diseases, including psychiatric disorders. 
Emerging evidence indicates that CNVs play a role in the genetic etiology 
of mental retardation, autism, schizophrenia, and bipolar disorders. This 
review summarizes the latest findings of recent research on the role of 
CNVs in the pathogenesis of these four psychiatric disorders. The positive 
association of CNVs with psychiatric disorders has several implications: 
(1) at least in some patients, the genetic defects in each patient are indi-
vidualized with high penetrance, which is different from the prevailing 
common variant hypothesis of complex psychiatric disorders; (2) the 
identification of pathogenic CNVs in psychiatric disorders would bring 
new insight into the pathogenesis of mental disorders; (3) array-based 
comparative genomic hybridization technology has the potential to 
become a useful laboratory tool in clinical practice to help in diagnosing 
psychiatric disorders. [Tzu Chi Med J 2009;21(3):197–203]
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1. Current status of genetic etiology 
studies of major psychiatric disorders
Schizophrenia, bipolar affective disorder, mental retar-
dation (MR), and autism are serious debilitating men-
tal disorders that together affect at least 1% of the 
general population. These disorders are chronic and 
result in impaired cognitive and social functioning in 
affected patients, and present a serious burden to 
their families and communities. Currently, pharma-
cotherapy is the treatment of choice for these disor-
ders. However, medication can only control the 
symptoms; there is no known cure. Hence, there is an 
urgent need to understand the etiology and the patho-
genesis of these disorders to develop new treatment 
for the affected patients.
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The search for the etiology of psychiatric disorders 
is a challenging task. Family, twin, and adoption 
studies have demonstrated a high influence of ge-
netic factors in the etiology of psychiatric disorders. 
However, except for a few cases, the genetic etiology 
of most patients remains elusive. The reasons for 
the difficulty in identifying the genetic defects related 
to psychiatric disorders can be attributed to the clin-
ical heterogeneity and the etiological heterogeneity 
in patients with psychiatric disorders.
Currently, two hypotheses guide the strategy of the 
genetic study of psychiatric disorders: the multiple 
common variants hypothesis and the individualized 
rare mutation hypothesis [1–3]. The multiple common 
variants hypothesis is the prevailing one, and proposes 
that mental disorders are the joint results of common 
variants of multiple genes that surpass a certain 
threshold, with each common variant contributing a 
small-to-modest risk. Based on this theory, numerous 
case-control association studies of candidate genes 
have been conducted [4,5]. Recently, with the avail-
ability of high throughput whole-genome single nu-
cleotide polymorphism (SNP) genotyping technology, 
the genome-wide association study has become the 
state-of-the-art approach in searching for susceptible 
genes of common complex diseases [6–9].
In contrast to the common variants hypothesis, the 
individualized rare mutation hypothesis of psychiat-
ric disorders postulates that psychiatric disorders are 
associated with rare mutations in certain important 
genes that have a high penetrance. These rare ge-
netic mutations are highly individualized in affected 
patients; each patient has his own specific disease-
associated mutation. Chromosomal abnormalities 
associated with psychiatric disorders provide a good 
example of the rare mutation hypothesis of complex 
psychiatric disorders. Numerous anecdotal case re-
ports of chromosomal abnormalities associated with 
psychiatric disorders can be found in the literature 
[10–12]. Most chromosomal abnormalities found in 
psychiatric patients are individualized rare mutations, 
with only a few being recurrent.
The association of chromosomal aberrations with 
psychiatric disorders indicates that genomic rearrange-
ment is one underlying genetic mechanism of psychi-
atric disorders, and that psychiatric disorders can 
also be considered as part of the genomic disorders. 
However, the yield of karyotyping analysis in psychiat-
ric patients is low; less than 1% of patients with schiz-
ophrenia, and less than 5% of patients with autism 
were found to have disease-associated chromosomal 
abnormalities. The low frequency of chromosomal 
abnormalities in psychiatric patients can be partly 
attributed to the limited resolution of conventional 
karyotyping analysis in detecting chromosomal dele-
tion and duplication, collectively known as copy number 
variations (CNVs). Recently, the development of whole 
genome array-based comparative genomic hybridiza-
tion (array CGH) technology has greatly facilitated 
the detection of submicroscopic CNVs, due to its im-
proved resolution; this is also known as the molecu-
lar karyotyping method [13,14].
Accumulating evidence, using array CGH, suggests 
that CNVs play an important role in the pathogenesis 
of psychiatric disorders. This review aims to summa-
rize the latest findings of recent research on the role 
of CNVs in the genetic etiology of major psychiatric 
disorders, including MR, schizophrenia, bipolar dis-
orders, and autism.
2. Population genetics of CNVs
CNVs are defined as gains and losses of DNA segments 
in the human genome, and cause human genome 
variations. The human genome has a high content of 
repetitive sequences that function as mediators to 
facilitate the formation of CNVs via unequal cross-
over [15–17]. Theoretically, the size of CNV can range 
from several base pairs to megabase pairs; however, 
in the current literature, the size of CNV is usually 
defined as larger than 1 kb. Three major platforms of 
array CGH that differ in the design of the probes are cur-
rently used to detect CNVs, including oligonucleotide-
based array [18], SNP array [19–21], and bacterial 
artificial chromosome-based array [22–24].
One recent study systematically investigated the 
occurrence of CNVs across the human genome in 270 
multiethnic subjects from the HapMap project, which 
provides an update overview of the population ge-
netics of CNVs. This study identified 3.048 CNVs from 
270 subjects, and 76% of these CNVs were larger than 
10 kb, while 64% of the CNVs were from 5 to 10 kb. 
CNVs larger than 50 kb were rare in this sample. 
Approximately half of the CNVs (1320 of 3048) were 
observed in multiple unrelated individuals, with the 
population frequency larger than 1%; these are referred 
to as copy number polymorphisms. As to the rare 
CNVs that accounted for the other half of the CNVs 
found in this study, the researchers found that the 
majority of rare CNVs (50 out of 60) were inherited 
from their parents [25]. Another study examined the 
CNVs in 300 Han Chinese from Taiwan and found some 
characteristic CNVs for this sample, suggesting that 
different populations have their own characteristic 
CNVs; this should be taken into consideration when 
conducting CNV studies in different populations [26].
CNVs contribute to genomic diversity and may in-
fluence the expression of genes located in and near 
the CNV regions. Hence, CNVs have a broad influence 
on the phenotypic spectrum of human traits, includ-
ing human diseases. CNVs associated with human 
diseases are referred to as pathogenic CNVs, and the 
related diseases are known as genomic disorders. 
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Genomic disorders are not new; several rare genetic 
diseases have been known to be associated with 
CNVs, such as Charcot-Marie-Tooth disease type 1A, 
hereditary neuropathy with liability to pressure pal-
sies [27], Bardet-Bidle syndrome [28], Smith-Magenis 
syndrome [29], velocardiofacial syndrome, and 
Williams-Beuren syndrome [30]. With the employ-
ment of array CGH technology, recent studies have 
discovered that submicroscopic CNVs play a role in the 
genetic mechanism of common complex diseases, 
especially in sporadic cases [31]. For example, CNVs 
were reported to be associated with autoimmune 
diseases, such as systemic lupus erythematosus, 
psoriasis, Crohn’s disease, rheumatoid arthritis, and 
diabetes mellitus type 1 [32]. Notably, accumulating 
data suggest that CNVs also play an essential role in 
neurodevelopmental disorders [33]. The association 
of CNVs with psychiatric disorders will be elaborated 
on in the following sections.
3. CNV and MR
MR is a childhood-onset neurodevelopmental disorder 
characterized by reduced intellectual function that 
results in learning disability and impaired social ad-
aptation. It is a highly heterogeneous disorder with 
a prevalence of 1–3% in the general population, and 
males are more often affected than females [34]. Ap-
proximately 10% of MR is due to gross chromosomal 
abnormalities, including chromosomal number aber-
rations, reciprocal translocation, insertions, and dele-
tions [35–37]. The advent of array CGH has increased 
the detection of cryptic chromosomal imbalances in 
MR that was not possible using routine karyotype 
analysis [38,39].
Two studies discovered gains and losses of DNA in 
13–21% of patients with apparently balanced trans-
location and an abnormal phenotype [40,41]. One 
study reported that in 117 karyotypically-normal pa-
tients diagnosed with unexplained MR (mild to severe) 
and/or congenital malformations, 18 pathogenic CNVs 
and nine potentially pathogenic CNVs were identified 
[42]. In a multicenter study, McMullan et al reported 
that 15% of 120 unexplained MR patients were found 
to have de novo CNVs [43]. Taken together, these 
studies support the utility of array CGH in detecting 
the chromosomal imbalances associated with MR and 
congenital anomalies, and the diagnostic yield has 
been increased by an additional 8–17% [44].
Three studies reported that recurrent microdele-
tions at 16p11.2 account for around 1% of autism. 
Interestingly, in a screening of 4284 patients with MR 
or multiple congenital anomalies, 22 individuals were 
found to have a 16p11.2 deletion. These individuals 
were not found to have autism, suggesting that sub-
jects with a 16p11.2 microdeletion may have varied 
clinical presentations ranging from MR, autism, learning 
and speech problems, to a normal phenotype [45].
Although array CGH is a useful tool to detect CNVs, 
it is sometimes difficult to distinguish the pathogenic 
from the benign. Webber’s group used a novel, statis-
tically robust approach that forges links between 
148 MR-associated CNVs and phenotypes from 
around 5000 mouse gene knockout experiments. 
Using this approach, they were able to identify 78 can-
didate genes that may contribute to MR and related 
phenotypes [46].
4. CNV and autism
Autism was first described by Leo Kanner in 1943 as 
a childhood neurodevelopmental disorder [47]. The 
term is one of the diagnoses within the category of per-
vasive developmental disorders, which also includes 
Rett syndrome, pervasive developmental disorders not 
otherwise specified, and Asperger’s syndrome. These 
diseases are also known as autism spectrum disorders 
(ASDs). The prevalence is 0.1–0.2% for autism and 
0.6% for ASDs [48]. Family, twin and adoption stud-
ies have shown that the genetic factor plays an im-
portant role in the etiology of ASDs; the estimated 
heritability of ASDs is approximately 90% [49,50].
The genetic underpinnings of ASDs are complex and 
remain largely unknown. Cytogenetic studies have 
shown that chromosomal structural aberrations such 
as translocation, inversion, deletion, and duplication 
account for approximately 3–5% of autism cases 
[19,51]. The employment of array CGH in the genetic 
study of ASDs revealed several novel submicroscopic 
CNVs associated with ASDs.
Three recent studies reported that a recurrent 
microdeletion at chromosome 16p11.2 is an impor-
tant CNV associated with autism. Weiss et al found 
that around 1% of idiopathic and non-syndromic au-
tism cases carried a ∼593 kb microdeletion and a re-
ciprocal duplication among a sample of multiplex 
families in the Autism Genetic Resource Exchange 
[21]. Kumar et al also discovered this recurrent 
microdeletion at 16p11.2 in around 0.6% of autism 
cases (absent in all controls) [22]. Marshall et al re-
ported the same 16p11.2 microdeletion in around 
1% of their sample that contained 427 unrelated ASD 
cases [20].
Duplication of chromosome 15q11-q13 accounts 
for another 1–3% of ASDs, and is the most frequently 
found duplication in ASDs. The parental origin of the 
duplication can influence the phenotype of the af-
fected patients [52]. Maternally derived duplications 
of chromosome 15q11–q13 confer a high risk of 
ASD (> 85%), in contrast to paternally derived dupli-
cations whose effects can range from none to mild 
developmental and cognitive impairment [51,53].
200 TZU CHI MED J  September 2009  Vol 21  No 3
Many rare genomic disorders, such as William 
syndrome (deletion at 7q11.23), Potocki-Lupski 
syndrome (duplication at 17p11.2), velocardio-
facial syndrome/DiGeorge syndrome (deletion at 
22q11.2), Prader-Willi syndrome (paternal deletion 
at 15q11.2-13) and Angelman syndrome (maternal 
deletion at 15q11.2-13) also present with ASD-like 
phenotypes. For example, more than 90% cases of 
Potocki-Lupski syndrome show features of ASD [53], 
and approximately 25% of patients with velocardio-
facial syndrome/DiGeorge syndrome have psychiatric 
manifestations that include schizophrenia, attention-
deficit hyperactivity disorder, and ASDs [54]. Taken 
together, these data indicate that some CNVs are 
disease-specific, while others have pleiotropic effects 
that affect many organs and tissues in affected pa-
tients, and lead to various clinical symptoms.
CNVs associated with autism can help identify 
susceptibility genes to autism; genes located at or 
near the CNV regions can be considered as candi-
date genes of autism. For example, ubiquitin protein 
ligase E3A (UBE3A) and gamma-aminobutyric acid A 
receptor beta 3 within the 15q11-q13 were reported 
as autism susceptibility genes [52,55]. The SHANK3 
gene, located within a recurrent deletion at 22q13 
associated with autism, was also reported to be a 
susceptibility gene of autism [18,56,57]. In an analy-
sis of genome-wide CNVs detected from a cohort of 
1336 ASD cases and 1110 controls of European an-
cestry, the NRGN1 and ASTN2 genes that encode 
neuronal cell-adhesion molecules, and the UBE3A, 
PARK2, and FBXO40 genes [58], the post-synaptic den-
sity genes, SHANK3, NLGN4, and NRXN1-PSD, and the 
synapse complex genes, DPP6, DPP10 and PCDH9, 
were found to be implicated in conferring suscepti-
bility to autism in the CNV study by Marshall et al [20]. 
Neurexin 1 (NRXN1) at chromosome 11p12-13 was 
also considered as a candidate gene of autism in a 
family-based genome-wide linkage and CNV analysis 
by the Autism Genome Project Consortium [19].
5. CNV and schizophrenia and bipolar 
disorders
Schizophrenia is a devastating lifetime brain disor-
der, characterized by hallucinations, delusions and 
cognitive deficits, beginning in late adolescence. 
Schizophrenia is also a complex genetic disorder 
with an estimated heritability up to 80% [59]. In spite 
of the high heritability, studies searching for genes 
linked to schizophrenia have been unsuccessful. The 
results from previous genome-wide linkage and case-
control association studies have not been as com-
pelling and consistent as those for other complex 
diseases, such as type 1 and type 2 diabetes mellitus. 
Even the most powerful method, the genome-wide 
association study, could not find a consistent sus-
ceptibility gene for schizophrenia. Recently, several 
reports supporting the association between CNVs 
and schizophrenia have been published. In this sec-
tion, we will discuss the evidence, possible mecha-
nisms, and implications of CNVs on the genetics of 
schizophrenia.
Several research groups from North America, 
South Africa and Europe found strong evidence that 
patients with schizophrenia carried an increased 
burden of rare (frequency < 1%) and large (> 100 kb) 
CNVs. One study reported that 15% of cases and 
20% of young-onset (< 18 years old) cases were found 
to have novel CNVs, versus 5% of controls in the first 
phase of the study. The proportion of these struc-
tural variants was 23% in childhood-onset cases ver-
sus 13% in their parents as controls in the second 
phase of the study, using independently replicated 
groups of subjects [60]. The other group found that 
the frequency of de novo CNVs in sporadic schizo-
phrenia was 10% versus 1.3% in controls [61]. The 
authors suggested that a rare de novo germ line mu-
tation of CNV events contributes to the vulnerability 
to schizophrenia. In addition to the de novo CNVs, 
several recurrent CNVs at 1q21.1, 15q11.2, 15q13.3 
and 22q11.2 were found in several studies with a 
large sample size. The frequency of recurrent CNVs 
at these “hot” loci was found in around 0.2–0.6% of 
schizophrenia patients, with an estimated odds ratio 
from 3 to 25 [62–64]. Nevertheless, one study showed 
a negative association between CNVs and schizo-
phrenia in a Han Chinese population [65]. The dis-
crepant results may be due to the sample size of this 
study (155 patients vs. 187 controls), or to the het-
erogeneity of the genetic etiology of schizophrenia in 
different populations.
In contrast to the often contradictory findings of 
traditional linkage and association studies, most 
studies on CNVs in schizophrenia are consistent with 
each other. The identification of CNVs associated 
with schizophrenia may also shed some light on the 
pathogenesis of schizophrenia, which can be re-
vealed through the change in gene dosage by dele-
tion, duplication, truncation, or the formation of a 
chimera gene in the CNV regions. For example, the 
gene dosage of CNTNAP2 encodes a transmembrane 
protein of the neurexin superfamily that mediates 
cell-cell interactions in the nervous system, and was 
associated with schizophrenia and epilepsy [66]. 
Recently, multiple deletions affecting NRXN1 exons 
that confer a risk of schizophrenia were reported by 
Rujescu et al [67]. Besides NRXN1, three additional 
candidate genes (MYT1L, CTNND2 and ASTN2) dis-
rupted by rare CNVs in schizophrenic patients were 
reported by Vrijenhoek et al [68]. Using pathway 
analysis, Walsh et al [60] found that rare schizophre-
nia-associated CNVs disproportionately occurred at 
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signaling networks controlling neurodevelopment, in-
cluding neuregulin and glutamate pathways. However, 
this result was not supported by another group [69]. 
The pathogenesis of CNVs associated with schizo-
phrenia may not be as straightforward as the disrup-
tion, or the gene dosage changes of candidate genes. 
Other mechanisms, such as altered gene expression, 
epigenetic modulation, pleiotropic effects and sec-
ond hit mutations, may also be involved.
The association between CNVs and bipolar disor-
der has been relatively less reported. Lachman et al 
reported a nominally significant association of the 
CNV containing GSK3β with bipolar disorder 
(p = 0.002) [70]. One genome-wide CNV survey showed 
increased singleton deletions (deletions that appear 
only once in the dataset) in bipolar disorder (cases, 
16.2% vs. controls, 12.3%; p = 0.007 with permuta-
tion). Moreover, a marginally greater overall burden 
of CNVs in patients with an earlier age (< 18 years 
old) at onset of mania was observed in the study 
(younger onset, 18.9% vs. older onset, 14.7%; p = 0.05) 
[71]. Based on this initial evidence, rare CNVs may 
also play a role in genetic vulnerability to bipolar dis-
order. Further studies with a large sample size are 
needed to address this issue.
6. Implications and perspectives of 
CNV in psychiatric disorders
What are the implications of the positive association 
of CNVs with psychiatric disorders? First, rare CNVs 
with high penetrance in the studies mentioned above 
support the “common disease, rare variants” hypoth-
esis, which may indicate a growing paradigm shift 
from the “common disease, common variants” hy-
pothesis in the genetic model of complex psychiatric 
disorders. The “common disease, common variants” 
hypothesis can explain the observed decline in the 
risk of recurrence of psychiatric disorders with the 
increased genetic distance from affected individuals. 
However, several features of psychiatric disorders 
support the “multiple rare alleles” model: (a) occa-
sionally, families have been severely affected, but no 
closely affected relatives were found; (b) increased 
paternal age is associated with an increased risk of 
psychiatric disorders, which is compatible with the 
increased rate of de novo germ line mutations with 
advancing paternal age; (c) decreased fecundity of 
psychiatric patients that would lead to a diminish-
ment of disease-associated alleles does not reduce 
the incidence and the prevalence of psychiatric dis-
orders, which can be explained by the ongoing 
de novo mutations in affected patients [72]. The as-
sociation of CNVs with psychiatric disorders lends 
support to the multiple rare variants hypothesis of 
psychiatric disorders. It is noteworthy that the two 
models are not mutually exclusive; they may be present 
in different subgroups of patients under the same 
psychiatric diagnosis.
Second, some patients with different psychiatric 
diagnoses shared a common CNV region associated 
with their disease, suggesting that there might be some 
common pathogenetic pathways underlying different 
psychiatric symptoms. For example, a common CNV 
at 16p11.2 was found in both schizophrenia and au-
tism, with deletion in autism and duplications in 
schizophrenia. It is thus proposed that schizophre-
nia and autism are disorders of the “social brain”, 
but at opposite ends of the same spectrum. As schiz-
ophrenia and other psychotic disorders result from 
“overdevelopment” of the social brain, ASD reflects 
underdevelopment [73].
Third, the mysteries of the origin and nature of 
CNVs are still unsolved. What is known is that certain 
human genomic regions are prone to recurrent CNV 
formation. Notably, genes involved in brain develop-
ment and synaptic plasticity are overrepresented at 
sites of CNVs [74]. From the viewpoint of evolution, 
the observation that this instability in humans is re-
cent in origin and tolerated at neural gene-rich sites 
may account for the development of intelligence in 
hominids. In other words, a relaxed control from brain 
function-associated regions of the human genome 
may result in our unique creativity and language abil-
ity. But mental disorders like schizophrenia, MR, bipo-
lar disorder, and autism may be a heavy price to pay 
for a smarter brain. It has been noted that environ-
ment stressors such as famine and/or severe psycho-
logical stress may increase CNV mutation rates either 
globally or at targeted genomic regions [75–77].
Finally, only CNVs greater than 50–100 kb have 
been assayed to date, and there are still many more 
loci and biological functions to be assessed. So far, 
the CNVs account for perhaps only 2–4% of schizo-
phrenia [78], and this varies with different popula-
tions. CNV studies provide a complementary approach 
to traditional SNP-based analyses, and may help us to 
uncover a part of the puzzling “missing heritability” 
in psychiatric genetics [79].
7. Summary
CNVs of genomic DNA are not new; they are already 
present in our genome. With the development of the 
new technology of array CGH, we are able to detect 
submicroscopic CNVs and start to understand their 
association with complex disorders, including men-
tal disorders. If CNVs can account for 5–10% of the 
genetic etiology of psychiatric patients, the array CGH 
would have a potential to be used as a laboratory 
test to help in the clinical diagnosis of psychiatric 
patients in clinical practice. In addition, studying the 
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impact of CNVs on the gene expression profile of 
affected patients would bring new insight into the 
pathogenesis of psychiatric disorders. This would 
contribute to the development of new treatments for 
psychiatric disorders in the future.
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